Level C· Early human research exploring benefitsProspective StudyEurope PMCOpen access

Bio-Oss<sup>®</sup>/Avitene™ composite scaffold promotes maxillofacial bone regeneration via early osteoimmunomodulation of BM-MSCs: an <i>in vitro</i> and clinical study

Iaquinta MR., De Pace R., D'Agostino A., Lonardi F., Trevisiol L., Lobbia G.

Prospective Study on Chronic Wound, Chronic Inflammation, Immune Modulation, published in Front Bioeng Biotechnol (2026) — summary generated from the PubMed abstract.

Open my reading list
Level C· Early human research exploring benefitsEvidence level of this study

Early human evidence such as case series or small samples is exploring possible benefits.

  • Level A · Stronger Clinical Evidence
  • Level B · Emerging clinical evidence with positive signals
  • Level C · Early human research exploring benefits
  • Level D · Scientific groundwork from lab and animal studies
  • Emerging · Emerging topic under active research
Read the A–D evidence level guide

This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.

Study type
Prospective Study
Journal
Front Bioeng Biotechnol (2026)
Reported sample size
—
Source database
Europe PMC
PMID
42358446
PMCID
PMC13291549
DOI
10.3389/fbioe.2026.1795343

Abstract (original English)

Inflammation is an important biological process to be considered in designing successful biomaterial-based therapeutics. Indeed, prolonged inflammation can result in delayed wound healing and, in some cases, may cause the rejection of the biomaterial together with additional tissue damage. Mesenchymal stem cells (MSCs) participate in this critical intercellular communication to modulate bone healing. In this study, MSCs were employed as in vitro model in order to evaluate the biological performances, in terms of immune response, of Bio-Oss®/Avitene™ composite scaffold. Moreover, new bone formation was evaluated in patients undergoing maxillomandibular osteotomy for skeletal malocclusion, facial asymmetry, or aesthetic indications, using a Bio-Oss®/Avitene™ composite scaffold. The early inflammatory response of human bone marrow derived-mesenchymal stem cells (BM-MSCs) was investigated in vitro analysing the gene expression of IL-6 and IL-8 using Droplet Digital PCR and the release of cytokines, chemokines, and growth factors using Bio-Plex approach. Clinical evaluation was performed using Cone Beam Computed Tomography (CBCT). In vitro , Bio-Oss®/Avitene™ decreases the IL-6 expression, quantified with Droplet Digital PCR approach. Bio-Plex reveals that the protein levels of MCP-1 and IL-6 were reduced, while IL-4, IL-8 and VEGF were increased by the scaffold in cells up to day 7

What this study does not prove

  • • This study does not prove SVF is an approved treatment or a replacement for standard care.

Evidence level

Early human evidence such as case series or small samples is exploring possible benefits.

How we grade evidence

Browse all related research

Filter the research library by this study's title keywords, author, or publication year.

Related research